DOCSLIB.ORG

(12) Patent Application Publication (10) Pub. No.: US 2007/0015833 A1 Flashner-Barak Et Al

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
(12) Patent Application Publication (10) Pub. No.: US 2007/0015833 A1 Flashner-Barak Et Al US 2007 OO15833A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2007/0015833 A1 Flashner-Barak et al. (43) Pub. Date: Jan. 18, 2007 (54) FORMULATIONS OF FENOFIBRATE Publication Classification CONTAINING MENTHOL (51) Int. Cl. A6II 3L/92 (2007.01) (76) Inventors: Moshe Flashner-Barak, Petach Tikva (52) U.S. Cl. .............................................................. 514/571 (IL); E. Itzhak Lerner, Petach Tikva (IL); Vered Rosenberger, Jerusalem (57) ABSTRACT (IL); Naomi Moldavski. D.N. HaNegev The invention provides at least a composition for the treat (IL) ment of elevated levels of triglycerides, comprising a thera peutically effective amount offenofibrate or another fibrate Correspondence Address: drug intimately associated with menthol, optionally in the KENYON & KENYON LLP presence of at least one surfactant mixture. The invention ONE BROADWAY also provides a method for the treatment of elevated levels NEW YORK, NY 10004 (US) of triglycerides in a Subject, comprising administering to the Subject a composition comprising a therapeutically effective amount of fenofibrate or another fibrate drug and menthol, (21) Appl. No.: 11/182,777 wherein the fenofibrate or the other fibrate drug is in intimate association with the menthol, wherein the menthol can be (22) Filed: Jul. 18, 2005 menthol or menthol Surfactant mixture. US 2007/0015833 A1 Jan. 18, 2007 FORMULATIONS OF FENOFIBRATE be reduced from 100 mg per dose to 67 mg per dose and then CONTAINING MENTHOL Subsequently to 54 mg per dose, all with the same bioavail ability in the fed state. Nanoparticle formulations of the drug BACKGROUND have further allowed the reduction of the dose to 48 mg per dose with the bioavailability of the “fasted state' being 0001 Fenofibrate, (2-4-(4-chlorobenzoyl) phenoxy-2- reported as similar to the fed state. There is still room for methyl-propanoic acid, 1-methylethyl ester) is one of the much improvement since it is posited that the true bioavail fibrate class of drugs. It is available as both capsules and ability of fenofibrate is still relatively low. The current tablets. Fenofibrate is apparently a prodrug. The active inventors have Surprisingly found that a composition of moiety is reportedly the metabolite fenofibric acid which is fenofibrate dissolved in menthol and comprising Surface reported to be produced in the body by esterases. When active agents gives a much enhanced bioavailability well dosing fenofibrate, apparently no intact fenofibrate is found beyond anything previously disclosed. The inventors have in the plasma (Physician's Desk Reference 58" ed., 2004, also surprisingly found formulations with or without men pages 522-525 (PDR)). thol of increased solubility and drug release offenofibrate 0002 Fenofibrate is a very poorly soluble drug. Despite its poor solubility, it is reported to be well absorbed when SUMMARY OF THE INVENTION dosed in the “fed state' and less so in the “fasted state'. It is unclear what the bioavailability of the fenofibric acid 0007. The present invention encompasses a composition really is, since much of it is understood to be metabolized to for the treatment of elevated levels of triglycerides that the glucuronide in both presystemic and first pass sites. The comprises a therapeutically effective amount offenofibrate absolute bioavailability offenofibrate cannot supposedly be or another fibrate drug that is intimately associated with determined since the compound is insoluble in media Suit menthol. The intimate association may be in the form of a able for intravenous injection. Following oral administration solution of the fenofibrate or other fibrate in menthol but in healthy volunteers, approximately 60% of a single dose of would encompass compositions where at least part of the radiolabelled fenofibrate appeared in urine, primarily as drug has come out of Such a solution due to a process that fenofibric acid and its glucuronide conjugate, and 25% was induces the precipitation of the drug, e.g. Saturation Such as excreted in the feces. (PDR) The absorption offenofibrate is reducing the Volume of the solvent or cooling. The compo understood to be increased when administered with food. sition may be optionally absorbed in, or adsorbed on a solid With fenofibrate tablets, the extent of absorption is increased carrier by methods exemplified by the teachings in US by approximately 35% when dosed with food (PDR, Mar 2003-0224059 and US 2004-0198646. tindale 33" ed. page 889). 0008. The present invention encompasses a composition for the treatment of elevated levels of triglycerides that 0003. Much effort has been expended to improve the comprises a therapeutically effective amount offenofibrate formulation of fenofibrate. U.S. Pat. Nos. 4,895,726 and or another fibrate drug that is dissolved in menthol and 5,880,148 disclose co-micronizing the fenofibrate with sur further comprises at least one Surface active agent. The face active agents. U.S. Pat. Nos. 6,074,670 and 6,277,405 composition may be optionally absorbed on a solid carrier. disclose micronized fenofibrate coated onto hydrosoluble carriers with optional surface active agents. U.S. Pat. No. 0009. The present invention encompasses a composition 6,814,977 discloses fenofibrate dissolved in a medium chain that comprises a therapeutically effective amount offenofi glycerolester of fatty acid, U.S. Pat. No. 6,719,999 discloses brate or another fibrate drug that is dissolved in menthol and fenofibrate dissolved in glycerin, propylene glycol, or dim further comprises at least one Surface active agent. The ethylisosorbide and U.S. Pat. No. 5,827,536 discloses composition can have a dissolution property in that, when fenofibrate dissolved in diethyleneglycol monoethyl ether. tested in 50 ml 0.1 NHCl at 37° C. and 150 rpm, at least about 10%, 30% or 80% of the fenofibrate or the other 0004 Several patents disclose specific formulations of fibrate drug dissolved in 15 minutes. The composition can micronized fenofibrate with specific polymeric or surface also have a dissolution property in that, when tested in 500 active agent additives while several others describe emul ml 0.5% Sodium lauryl sulfate (SLS) in water at 37° C. and sions and suspensions. US Patent Application Publication 50 rpm, at least about 70% of the fenofibrate or the other No. 20040087656 discloses fenofibrate of particle size less than 2000 nm with an improved bioavailability. US Patent fibrate drug dissolved in 5 minutes. Application Publication No. 20030224059 discloses micro 0010. The present invention encompasses a composition particles of active pharmaceutical ingredients, drug delivery that comprises a therapeutically effective amount offenofi vehicles comprising same, and methods for making them. brate or another fibrate drug that is dissolved in menthol and The disclosure of US20030224059 is incorporated herein by further comprises at least one surface active agent that when reference in its entirety. administered orally to beagle dogs shows a bioavailability of fenofibric acid based on Area Under the Curve (AUC) of the 0005 US Patent Application Publication No. concentration V. time profile in plasma that is at least three 20040198646 discloses compositions comprising solutions times that of the Trichor R. 54 mg product on a per milligram of drugs in menthol, especially drugs that are poorly soluble basis (when normalized to equal weight). in water, and to methods for making Such compositions. The disclosure of US200401986.46 is incorporated in its entirety 0011. The present invention also encompasses the by reference. method of preparing a composition of the invention, which method comprises: 0006 Micronization of the drug and the addition of Surface active agents have moderately raised the bioavail 0012 a) heating menthol to about 60° C. in order to ability of fenofibrate allowing the amount of drug dosed to effect melting thereof, US 2007/0015833 A1 Jan. 18, 2007 0013 b) adding at least one surface active agent to the lyceridemia. The term “fenofibrate' includes the 1-methyl melt, ethyl ester of 2-4-(4-chlorobenzoyl)-phenoxy-2-methyl propanoic acid and any pharmaceutically acceptable salts 0014) c) cooling the product of step b) to about 50° C., thereof. One aspect of this invention is to compositions of 0015 d) dissolving fenofibrate or another fibrate drug fenofibrate that is dissolved in menthol. Fenofibrate dis in the product of step c) with stirring, solves up to about 37% in melted menthol at 60° C. Formulations may be made where all the fenofibrate is 0016 e) cooling9. the pproduct of stepp d) to room tem dissolved in the menthol or where only some of the fenofi perature to obtain the composition of the invention, and brate is so dissolved and the rest present in a solid form in 0017 f) if capsules are desired. (A) dispensing the the fully saturated menthol medium. In a preferred embodi product of step e) into capsules, or (B) alternatively ment of the invention, the fenofibrate is fully dissolved in the menthol. In one embodiment of the invention, the menthol adding a solid carrier Such as microcrystalline cellu melt may be filled into capsules in the liquid state or may be lose, lactose or Sorbitol, to the product of step e), solidified, optionally milled, and filled into capsules. The mixing well, cooling to room temperature and filling capsules used for the liquid fill in one embodiment may be the powder thus obtained into capsules. hard gelatin capsules. In a preferred embodiment, the hard 0018. The present invention encompasses a composition gelatin capsules are banded to prevent leakage. In a more that comprises a therapeutically effective amount offenofi preferred embodiment, the liquid formulation may be filled brate or another fibrate drug that is dissolved in a surfactant into soft-gel capsules. In another embodiment, the Solidified mixture, such as Polyethylene Glycol (PEG) 1000 and menthol solution is optionally milled and filled into hard Poloxamer 407. The composition may be optionally gelatin capsules or equivalent capsules of other materials absorbed or adsorbed on a solid carrier.
Load more

Recommended publications
  • )&F1y3x PHARMACEUTICAL APPENDIX to THE
    )&f1y3X PHARMACEUTICAL APPENDIX TO THE HARMONIZED TARIFF SCHEDULE )&f1y3X PHARMACEUTICAL APPENDIX TO THE TARIFF SCHEDULE 3 Table 1. This table enumerates products described by International Non-proprietary Names (INN) which shall be entered free of duty under general note 13 to the tariff schedule. The Chemical Abstracts Service (CAS) registry numbers also set forth in this table are included to assist in the identification of the products concerned. For purposes of the tariff schedule, any references to a product enumerated in this table includes such product by whatever name known. Product CAS No. Product CAS No. ABAMECTIN 65195-55-3 ACTODIGIN 36983-69-4 ABANOQUIL 90402-40-7 ADAFENOXATE 82168-26-1 ABCIXIMAB 143653-53-6 ADAMEXINE 54785-02-3 ABECARNIL 111841-85-1 ADAPALENE 106685-40-9 ABITESARTAN 137882-98-5 ADAPROLOL 101479-70-3 ABLUKAST 96566-25-5 ADATANSERIN 127266-56-2 ABUNIDAZOLE 91017-58-2 ADEFOVIR 106941-25-7 ACADESINE 2627-69-2 ADELMIDROL 1675-66-7 ACAMPROSATE 77337-76-9 ADEMETIONINE 17176-17-9 ACAPRAZINE 55485-20-6 ADENOSINE PHOSPHATE 61-19-8 ACARBOSE 56180-94-0 ADIBENDAN 100510-33-6 ACEBROCHOL 514-50-1 ADICILLIN 525-94-0 ACEBURIC ACID 26976-72-7 ADIMOLOL 78459-19-5 ACEBUTOLOL 37517-30-9 ADINAZOLAM 37115-32-5 ACECAINIDE 32795-44-1 ADIPHENINE 64-95-9 ACECARBROMAL 77-66-7 ADIPIODONE 606-17-7 ACECLIDINE 827-61-2 ADITEREN 56066-19-4 ACECLOFENAC 89796-99-6 ADITOPRIM 56066-63-8 ACEDAPSONE 77-46-3 ADOSOPINE 88124-26-9 ACEDIASULFONE SODIUM 127-60-6 ADOZELESIN 110314-48-2 ACEDOBEN 556-08-1 ADRAFINIL 63547-13-7 ACEFLURANOL 80595-73-9 ADRENALONE
    [Show full text]
  • Partial Agreement in the Social and Public Health Field
    COUNCIL OF EUROPE COMMITTEE OF MINISTERS (PARTIAL AGREEMENT IN THE SOCIAL AND PUBLIC HEALTH FIELD) RESOLUTION AP (88) 2 ON THE CLASSIFICATION OF MEDICINES WHICH ARE OBTAINABLE ONLY ON MEDICAL PRESCRIPTION (Adopted by the Committee of Ministers on 22 September 1988 at the 419th meeting of the Ministers' Deputies, and superseding Resolution AP (82) 2) AND APPENDIX I Alphabetical list of medicines adopted by the Public Health Committee (Partial Agreement) updated to 1 July 1988 APPENDIX II Pharmaco-therapeutic classification of medicines appearing in the alphabetical list in Appendix I updated to 1 July 1988 RESOLUTION AP (88) 2 ON THE CLASSIFICATION OF MEDICINES WHICH ARE OBTAINABLE ONLY ON MEDICAL PRESCRIPTION (superseding Resolution AP (82) 2) (Adopted by the Committee of Ministers on 22 September 1988 at the 419th meeting of the Ministers' Deputies) The Representatives on the Committee of Ministers of Belgium, France, the Federal Republic of Germany, Italy, Luxembourg, the Netherlands and the United Kingdom of Great Britain and Northern Ireland, these states being parties to the Partial Agreement in the social and public health field, and the Representatives of Austria, Denmark, Ireland, Spain and Switzerland, states which have participated in the public health activities carried out within the above-mentioned Partial Agreement since 1 October 1974, 2 April 1968, 23 September 1969, 21 April 1988 and 5 May 1964, respectively, Considering that the aim of the Council of Europe is to achieve greater unity between its members and that this
    [Show full text]
  • Regulation of Pharmaceutical Prices: Evidence from a Reference Price Reform in Denmark
    A Service of Leibniz-Informationszentrum econstor Wirtschaft Leibniz Information Centre Make Your Publications Visible. zbw for Economics Kaiser, Ulrich; Mendez, Susan J.; Rønde, Thomas Working Paper Regulation of pharmaceutical prices: Evidence from a reference price reform in Denmark ZEW Discussion Papers, No. 10-062 Provided in Cooperation with: ZEW - Leibniz Centre for European Economic Research Suggested Citation: Kaiser, Ulrich; Mendez, Susan J.; Rønde, Thomas (2010) : Regulation of pharmaceutical prices: Evidence from a reference price reform in Denmark, ZEW Discussion Papers, No. 10-062, Zentrum für Europäische Wirtschaftsforschung (ZEW), Mannheim This Version is available at: http://hdl.handle.net/10419/41440 Standard-Nutzungsbedingungen: Terms of use: Die Dokumente auf EconStor dürfen zu eigenen wissenschaftlichen Documents in EconStor may be saved and copied for your Zwecken und zum Privatgebrauch gespeichert und kopiert werden. personal and scholarly purposes. Sie dürfen die Dokumente nicht für öffentliche oder kommerzielle You are not to copy documents for public or commercial Zwecke vervielfältigen, öffentlich ausstellen, öffentlich zugänglich purposes, to exhibit the documents publicly, to make them machen, vertreiben oder anderweitig nutzen. publicly available on the internet, or to distribute or otherwise use the documents in public. Sofern die Verfasser die Dokumente unter Open-Content-Lizenzen (insbesondere CC-Lizenzen) zur Verfügung gestellt haben sollten, If the documents have been made available under an Open gelten abweichend von diesen Nutzungsbedingungen die in der dort Content Licence (especially Creative Commons Licences), you genannten Lizenz gewährten Nutzungsrechte. may exercise further usage rights as specified in the indicated licence. www.econstor.eu Dis cus si on Paper No. 10-062 Regulation of Pharmaceutical Prices: Evidence from a Reference Price Reform in Denmark Ulrich Kaiser, Susan J.
    [Show full text]
  • Marrakesh Agreement Establishing the World Trade Organization
    No. 31874 Multilateral Marrakesh Agreement establishing the World Trade Organ ization (with final act, annexes and protocol). Concluded at Marrakesh on 15 April 1994 Authentic texts: English, French and Spanish. Registered by the Director-General of the World Trade Organization, acting on behalf of the Parties, on 1 June 1995. Multilat ral Accord de Marrakech instituant l©Organisation mondiale du commerce (avec acte final, annexes et protocole). Conclu Marrakech le 15 avril 1994 Textes authentiques : anglais, français et espagnol. Enregistré par le Directeur général de l'Organisation mondiale du com merce, agissant au nom des Parties, le 1er juin 1995. Vol. 1867, 1-31874 4_________United Nations — Treaty Series • Nations Unies — Recueil des Traités 1995 Table of contents Table des matières Indice [Volume 1867] FINAL ACT EMBODYING THE RESULTS OF THE URUGUAY ROUND OF MULTILATERAL TRADE NEGOTIATIONS ACTE FINAL REPRENANT LES RESULTATS DES NEGOCIATIONS COMMERCIALES MULTILATERALES DU CYCLE D©URUGUAY ACTA FINAL EN QUE SE INCORPOR N LOS RESULTADOS DE LA RONDA URUGUAY DE NEGOCIACIONES COMERCIALES MULTILATERALES SIGNATURES - SIGNATURES - FIRMAS MINISTERIAL DECISIONS, DECLARATIONS AND UNDERSTANDING DECISIONS, DECLARATIONS ET MEMORANDUM D©ACCORD MINISTERIELS DECISIONES, DECLARACIONES Y ENTEND MIENTO MINISTERIALES MARRAKESH AGREEMENT ESTABLISHING THE WORLD TRADE ORGANIZATION ACCORD DE MARRAKECH INSTITUANT L©ORGANISATION MONDIALE DU COMMERCE ACUERDO DE MARRAKECH POR EL QUE SE ESTABLECE LA ORGANIZACI N MUND1AL DEL COMERCIO ANNEX 1 ANNEXE 1 ANEXO 1 ANNEX
    [Show full text]
  • Anatomical Classification Guidelines V2021 EPHMRA ANATOMICAL CLASSIFICATION GUIDELINES 2021
    EPHMRA ANATOMICAL CLASSIFICATION GUIDELINES 2021 Anatomical Classification Guidelines V2021 "The Anatomical Classification of Pharmaceutical Products has been developed and maintained by the European Pharmaceutical Marketing Research Association (EphMRA) and is therefore the intellectual property of this Association. EphMRA's Classification Committee prepares the guidelines for this classification system and takes care for new entries, changes and improvements in consultation with the product's manufacturer. The contents of the Anatomical Classification of Pharmaceutical Products remain the copyright to EphMRA. Permission for use need not be sought and no fee is required. We would appreciate, however, the acknowledgement of EphMRA Copyright in publications etc. Users of this classification system should keep in mind that Pharmaceutical markets can be segmented according to numerous criteria." © EphMRA 2021 Anatomical Classification Guidelines V2021 CONTENTS PAGE INTRODUCTION A ALIMENTARY TRACT AND METABOLISM 1 B BLOOD AND BLOOD FORMING ORGANS 28 C CARDIOVASCULAR SYSTEM 36 D DERMATOLOGICALS 51 G GENITO-URINARY SYSTEM AND SEX HORMONES 58 H SYSTEMIC HORMONAL PREPARATIONS (EXCLUDING SEX HORMONES) 68 J GENERAL ANTI-INFECTIVES SYSTEMIC 72 K HOSPITAL SOLUTIONS 88 L ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS 96 M MUSCULO-SKELETAL SYSTEM 106 N NERVOUS SYSTEM 111 P PARASITOLOGY 122 R RESPIRATORY SYSTEM 124 S SENSORY ORGANS 136 T DIAGNOSTIC AGENTS 143 V VARIOUS 145 Anatomical Classification Guidelines V2021 INTRODUCTION The Anatomical Classification was initiated in 1971 by EphMRA. It has been developed jointly by Intellus/PBIRG and EphMRA. It is a subjective method of grouping certain pharmaceutical products and does not represent any particular market, as would be the case with any other classification system.
    [Show full text]
  • PHARMACEUTICAL APPENDIX to the HARMONIZED TARIFF SCHEDULE Harmonized Tariff Schedule of the United States (2008) (Rev
    Harmonized Tariff Schedule of the United States (2008) (Rev. 2) Annotated for Statistical Reporting Purposes PHARMACEUTICAL APPENDIX TO THE HARMONIZED TARIFF SCHEDULE Harmonized Tariff Schedule of the United States (2008) (Rev. 2) Annotated for Statistical Reporting Purposes PHARMACEUTICAL APPENDIX TO THE TARIFF SCHEDULE 2 Table 1. This table enumerates products described by International Non-proprietary Names (INN) which shall be entered free of duty under general note 13 to the tariff schedule. The Chemical Abstracts Service (CAS) registry numbers also set forth in this table are included to assist in the identification of the products concerned. For purposes of the tariff schedule, any references to a product enumerated in this table includes such product by whatever name known. ABACAVIR 136470-78-5 ACIDUM GADOCOLETICUM 280776-87-6 ABAFUNGIN 129639-79-8 ACIDUM LIDADRONICUM 63132-38-7 ABAMECTIN 65195-55-3 ACIDUM SALCAPROZICUM 183990-46-7 ABANOQUIL 90402-40-7 ACIDUM SALCLOBUZICUM 387825-03-8 ABAPERIDONUM 183849-43-6 ACIFRAN 72420-38-3 ABARELIX 183552-38-7 ACIPIMOX 51037-30-0 ABATACEPTUM 332348-12-6 ACITAZANOLAST 114607-46-4 ABCIXIMAB 143653-53-6 ACITEMATE 101197-99-3 ABECARNIL 111841-85-1 ACITRETIN 55079-83-9 ABETIMUSUM 167362-48-3 ACIVICIN 42228-92-2 ABIRATERONE 154229-19-3 ACLANTATE 39633-62-0 ABITESARTAN 137882-98-5 ACLARUBICIN 57576-44-0 ABLUKAST 96566-25-5 ACLATONIUM NAPADISILATE 55077-30-0 ABRINEURINUM 178535-93-8 ACODAZOLE 79152-85-5 ABUNIDAZOLE 91017-58-2 ACOLBIFENUM 182167-02-8 ACADESINE 2627-69-2 ACONIAZIDE 13410-86-1 ACAMPROSATE
    [Show full text]
  • 2 12/ 35 74Al
    (12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (10) International Publication Number (43) International Publication Date 22 March 2012 (22.03.2012) 2 12/ 35 74 Al (51) International Patent Classification: (81) Designated States (unless otherwise indicated, for every A61K 9/16 (2006.01) A61K 9/51 (2006.01) kind of national protection available): AE, AG, AL, AM, A61K 9/14 (2006.01) AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, (21) International Application Number: DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, PCT/EP201 1/065959 HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, (22) International Filing Date: KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, 14 September 201 1 (14.09.201 1) ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PE, PG, PH, PL, PT, QA, RO, RS, RU, (25) Filing Language: English RW, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, (26) Publication Language: English TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. (30) Priority Data: 61/382,653 14 September 2010 (14.09.2010) US (84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, (71) Applicant (for all designated States except US): GM, KE, LR, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, NANOLOGICA AB [SE/SE]; P.O Box 8182, S-104 20 ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, Stockholm (SE).
    [Show full text]
  • Anatomical Classification Guidelines V2020 EPHMRA ANATOMICAL
    EPHMRA ANATOMICAL CLASSIFICATION GUIDELINES 2020 Anatomical Classification Guidelines V2020 "The Anatomical Classification of Pharmaceutical Products has been developed and maintained by the European Pharmaceutical Marketing Research Association (EphMRA) and is therefore the intellectual property of this Association. EphMRA's Classification Committee prepares the guidelines for this classification system and takes care for new entries, changes and improvements in consultation with the product's manufacturer. The contents of the Anatomical Classification of Pharmaceutical Products remain the copyright to EphMRA. Permission for use need not be sought and no fee is required. We would appreciate, however, the acknowledgement of EphMRA Copyright in publications etc. Users of this classification system should keep in mind that Pharmaceutical markets can be segmented according to numerous criteria." © EphMRA 2020 Anatomical Classification Guidelines V2020 CONTENTS PAGE INTRODUCTION A ALIMENTARY TRACT AND METABOLISM 1 B BLOOD AND BLOOD FORMING ORGANS 28 C CARDIOVASCULAR SYSTEM 35 D DERMATOLOGICALS 50 G GENITO-URINARY SYSTEM AND SEX HORMONES 57 H SYSTEMIC HORMONAL PREPARATIONS (EXCLUDING SEX HORMONES) 65 J GENERAL ANTI-INFECTIVES SYSTEMIC 69 K HOSPITAL SOLUTIONS 84 L ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS 92 M MUSCULO-SKELETAL SYSTEM 102 N NERVOUS SYSTEM 107 P PARASITOLOGY 118 R RESPIRATORY SYSTEM 120 S SENSORY ORGANS 132 T DIAGNOSTIC AGENTS 139 V VARIOUS 141 Anatomical Classification Guidelines V2020 INTRODUCTION The Anatomical Classification was initiated in 1971 by EphMRA. It has been developed jointly by Intellus/PBIRG and EphMRA. It is a subjective method of grouping certain pharmaceutical products and does not represent any particular market, as would be the case with any other classification system.
    [Show full text]
  • Stembook 2018.Pdf
    The use of stems in the selection of International Nonproprietary Names (INN) for pharmaceutical substances FORMER DOCUMENT NUMBER: WHO/PHARM S/NOM 15 WHO/EMP/RHT/TSN/2018.1 © World Health Organization 2018 Some rights reserved. This work is available under the Creative Commons Attribution-NonCommercial-ShareAlike 3.0 IGO licence (CC BY-NC-SA 3.0 IGO; https://creativecommons.org/licenses/by-nc-sa/3.0/igo). Under the terms of this licence, you may copy, redistribute and adapt the work for non-commercial purposes, provided the work is appropriately cited, as indicated below. In any use of this work, there should be no suggestion that WHO endorses any specific organization, products or services. The use of the WHO logo is not permitted. If you adapt the work, then you must license your work under the same or equivalent Creative Commons licence. If you create a translation of this work, you should add the following disclaimer along with the suggested citation: “This translation was not created by the World Health Organization (WHO). WHO is not responsible for the content or accuracy of this translation. The original English edition shall be the binding and authentic edition”. Any mediation relating to disputes arising under the licence shall be conducted in accordance with the mediation rules of the World Intellectual Property Organization. Suggested citation. The use of stems in the selection of International Nonproprietary Names (INN) for pharmaceutical substances. Geneva: World Health Organization; 2018 (WHO/EMP/RHT/TSN/2018.1). Licence: CC BY-NC-SA 3.0 IGO. Cataloguing-in-Publication (CIP) data.
    [Show full text]
  • Section B Changed Classes/Guidelines Final Version Date of Issue
    EPHMRA ANATOMICAL CLASSIFICATION GUIDELINES 2021 Section B Changed Classes/Guidelines Final Version Date of issue: 19th December 2020 1 A2B ANTIULCERANTS r2020 Combinations of specific antiulcerants with other substances, such as anti- infectives against Helicobacter pylori, antispasmodics, gastroprokinetics, that are for ulcers, gastro-oesophageal reflux disease or similar conditions are classified according to the antiulcerant substance. For example, proton pump inhibitors in combination with these anti-infectives are classified in A2B2. Combinations of antiulcerants with non-steroidal anti-inflammatories where the antiulcerant is present for gastric protection are classified in M1A1. A2B1 H2 antagonists R2002 Includes, for example, cimetidine, famotidine, nizatidine, ranitidine, roxatidine. Combinations of low dose H2 antagonists with antacids are classified with antacids in A2A6. A2B2 Proton pump inhibitors r2021 Includes esomeprazole, lansoprazole, omeprazole, pantoprazole, rabeprazole. Combinations of proton pump inhibitors with gastroprokinetics for ulcers, gastro- oesophageal disease or similar conditions are classified here. Includes potassium- competitive acid blockers (P-CABs) such as revaprazan, tegoprazan, vonoprazan, etc. A2B3 Prostaglandin antiulcerants Includes misoprostol, enprostil. A2B4 Bismuth antiulcerants Includes combinations with antacids. A2B9 All other antiulcerants r2020 Includes all other products containing substances with antiulcerant action where the type of substance is not specified in classes A2B1 to
    [Show full text]
  • (12) Patent Application Publication (10) Pub. No.: US 2014/0099333 A1 SCHWINK Et Al
    US 2014.0099333A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2014/0099333 A1 SCHWINK et al. (43) Pub. Date: Apr. 10, 2014 (54) PYRROLIDINONE DERVATIVES AS GPR119 Publication Classification MODULATORS FOR THE TREATMENT OF DLABETES, OBESITY, DYSLIPIDEMIA AND (51) Int. C. RELATED DSORDERS A 6LX3L/2197 (2006.01) A613 L/405 (2006.01) (71) Applicants: Lothar SCHWINK, Frankfurt am Main C07D 40/12 (2006.01) (DE); Martin BOSSART, Frankfurt am A613 L/4439 (2006.01) Main (DE); Heiner GLOMBIK, A613 L/4545 (2006.01) Frankfurt am Main (DE); Matthias C07D 405/4 (2006.01) GOSSEL, Frankfurt am Main (DE); C07D40 L/4 (2006.01) Dieter KADEREIT, Frankfurt am Main A61K3I/444 (2006.01) (DE); Thomas KLABUNDE, Frankfurt C07D 413/4 (2006.01) am Main (DE); Thomas MAIER, A6II 45/06 (2006.01) Frankfurt am Main (DE); Siegfried C07D 207/12 (2006.01) STENGELIN, Frankfurt am Main (DE) C07D 417/4 (2006.01) (52) U.S. C. (72) Inventors: Lothar SCHWINK, Frankfurt am Main CPC ............ A6IK3I/497 (2013.01); C07D 207/12 (DE); Martin BOSSART, Frankfurt am (2013.01); A61 K3I/4015 (2013.01); C07D Main (DE); Heiner GLOMBIK, 401/12 (2013.01); A61 K3I/4439 (2013.01); Frankfurt am Main (DE); Matthias C07D 417/14 (2013.01); C07D405/14 GOSSEL, Frankfurt am Main (DE); (2013.01); C07D 401/14 (2013.01); A61 K Dieter KADEREIT, Frankfurt am Main 3 1/444 (2013.01); C07D 413/14 (2013.01); (DE); Thomas KLABUNDE, Frankfurt A61K 45/06 (2013.01); A61 K3I/4545 am Main (DE); Thomas MAIER, (2013.01) Frankfurt am Main (DE); Siegfried USPC ....
    [Show full text]
  • Harmonized Tariff Schedule of the United States (2004) -- Supplement 1 Annotated for Statistical Reporting Purposes
    Harmonized Tariff Schedule of the United States (2004) -- Supplement 1 Annotated for Statistical Reporting Purposes PHARMACEUTICAL APPENDIX TO THE HARMONIZED TARIFF SCHEDULE Harmonized Tariff Schedule of the United States (2004) -- Supplement 1 Annotated for Statistical Reporting Purposes PHARMACEUTICAL APPENDIX TO THE TARIFF SCHEDULE 2 Table 1. This table enumerates products described by International Non-proprietary Names (INN) which shall be entered free of duty under general note 13 to the tariff schedule. The Chemical Abstracts Service (CAS) registry numbers also set forth in this table are included to assist in the identification of the products concerned. For purposes of the tariff schedule, any references to a product enumerated in this table includes such product by whatever name known. Product CAS No. Product CAS No. ABACAVIR 136470-78-5 ACEXAMIC ACID 57-08-9 ABAFUNGIN 129639-79-8 ACICLOVIR 59277-89-3 ABAMECTIN 65195-55-3 ACIFRAN 72420-38-3 ABANOQUIL 90402-40-7 ACIPIMOX 51037-30-0 ABARELIX 183552-38-7 ACITAZANOLAST 114607-46-4 ABCIXIMAB 143653-53-6 ACITEMATE 101197-99-3 ABECARNIL 111841-85-1 ACITRETIN 55079-83-9 ABIRATERONE 154229-19-3 ACIVICIN 42228-92-2 ABITESARTAN 137882-98-5 ACLANTATE 39633-62-0 ABLUKAST 96566-25-5 ACLARUBICIN 57576-44-0 ABUNIDAZOLE 91017-58-2 ACLATONIUM NAPADISILATE 55077-30-0 ACADESINE 2627-69-2 ACODAZOLE 79152-85-5 ACAMPROSATE 77337-76-9 ACONIAZIDE 13410-86-1 ACAPRAZINE 55485-20-6 ACOXATRINE 748-44-7 ACARBOSE 56180-94-0 ACREOZAST 123548-56-1 ACEBROCHOL 514-50-1 ACRIDOREX 47487-22-9 ACEBURIC ACID 26976-72-7
    [Show full text]